Table 3 Independent predictors of hypotension and atrial fibrillation following levosimendan treatment (within 6 days)
From: Overview of the current use of levosimendan in France: a prospective observational cohort study
Patient characteristics | Hypotension | Atrial fibrillation | ||
|---|---|---|---|---|
Odds ratio | 95% confidence interval | Odds ratio | 95% confidence interval | |
Age (10-year increment) | 1.03 | 1.006–1.05 | 1.03 | 1.02–1.05 |
Renal replacement therapy at the start of the treatment | 1.22 | 1.08–1.38 | NS | |
SOFA score at the start of the treatment | NS | 1.008 | 1.0005–1.01 | |
Levosimendan infusion rate (0.1 µg/kg/min increment) | NS | 1.06 | 1.01–1.10 | |
Hypotension following treatment | – | – | 1.07 | 1.01–1.13 |
Atrial fibrillation following treatment | 1.18 | 1.05–1.31 | – | – |